Steve Schey

2.5k total citations
45 papers, 1.4k citations indexed

About

Steve Schey is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Steve Schey has authored 45 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Hematology, 23 papers in Oncology and 18 papers in Molecular Biology. Recurrent topics in Steve Schey's work include Multiple Myeloma Research and Treatments (26 papers), Protein Degradation and Inhibitors (13 papers) and Peptidase Inhibition and Analysis (10 papers). Steve Schey is often cited by papers focused on Multiple Myeloma Research and Treatments (26 papers), Protein Degradation and Inhibitors (13 papers) and Peptidase Inhibition and Analysis (10 papers). Steve Schey collaborates with scholars based in United Kingdom, France and Australia. Steve Schey's co-authors include Henrik Møller, Karen Phekoo, Matthew Streetly, Mabel Aoun, Raoul Herbrecht, A Oakhill, B Gibson, F. Jacobs, Philip Darbyshire and Ian Hann and has published in prestigious journals such as Blood, British Journal of Cancer and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

Steve Schey

45 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Steve Schey United Kingdom 17 651 534 342 307 295 45 1.4k
H Demuynck Belgium 16 884 1.4× 484 0.9× 160 0.5× 204 0.7× 266 0.9× 39 1.5k
Naohito Fujishima Japan 19 598 0.9× 326 0.6× 167 0.5× 108 0.4× 257 0.9× 63 1.4k
A. C. Newland United Kingdom 20 439 0.7× 329 0.6× 179 0.5× 136 0.4× 193 0.7× 57 1.3k
Akiyoshi Miwa Japan 14 517 0.8× 402 0.8× 319 0.9× 81 0.3× 212 0.7× 79 1.1k
Jean El Cheikh France 28 1.8k 2.8× 804 1.5× 419 1.2× 203 0.7× 142 0.5× 163 2.3k
Roberta Schiavo Italy 19 399 0.6× 687 1.3× 213 0.6× 110 0.4× 137 0.5× 40 1.3k
P Ernst Denmark 12 635 1.0× 402 0.8× 76 0.2× 295 1.0× 152 0.5× 31 1.1k
Jae‐Ho Yoon South Korea 21 1.1k 1.6× 420 0.8× 372 1.1× 137 0.4× 87 0.3× 175 1.6k
Valérie Coiteux France 16 351 0.5× 244 0.5× 290 0.8× 143 0.5× 142 0.5× 55 836
Anna Gayà Spain 21 655 1.0× 235 0.4× 495 1.4× 210 0.7× 105 0.4× 51 2.1k

Countries citing papers authored by Steve Schey

Since Specialization
Citations

This map shows the geographic impact of Steve Schey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steve Schey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steve Schey more than expected).

Fields of papers citing papers by Steve Schey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steve Schey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steve Schey. The network helps show where Steve Schey may publish in the future.

Co-authorship network of co-authors of Steve Schey

This figure shows the co-authorship network connecting the top 25 collaborators of Steve Schey. A scholar is included among the top collaborators of Steve Schey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steve Schey. Steve Schey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ramsenthaler, Christina, et al.. (2017). Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) was established using traditional, generalizability and Rasch psychometric methods. Quality of Life Research. 26(11). 2931–2947. 5 indexed citations
2.
3.
Schey, Steve, Sarah Brown, Kwee Yong, et al.. (2015). Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial. British Journal of Haematology. 170(3). 336–348. 16 indexed citations
4.
Brown, Ruth E., et al.. (2012). Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales. The European Journal of Health Economics. 14(3). 507–514. 29 indexed citations
5.
Schey, Steve & Irene J Higginson. (2010). Cost–effectiveness of lenalidomide in multiple myeloma. Expert Review of Pharmacoeconomics & Outcomes Research. 10(3). 229–238. 6 indexed citations
6.
Schey, Steve. (2008). Survival from multiple myeloma in England and Wales up to 2001. British Journal of Cancer. 99(S1). S113–S115. 2 indexed citations
7.
Child, J. Anthony, Nigel H. Russell, Pieter Sonneveld, & Steve Schey. (2005). Future Directions in Multiple Myeloma Treatment. Acta Haematologica. 114(Suppl. 1). 8–13. 4 indexed citations
8.
Streetly, Matthew, Beverley J. Hunt, Kiran Parmar, et al.. (2005). Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent ActimidTM (CC‐4047) and their relationship with venous thrombosis. European Journal Of Haematology. 74(4). 293–296. 29 indexed citations
9.
Kazmi, M, et al.. (2004). Second autologous transplant with cyclosporin/interferon α-induced graft versus host disease for patients who have failed first-line consolidation. Bone Marrow Transplantation. 33(11). 1131–1135. 6 indexed citations
10.
Cormican, Liam, Steve Schey, & Heather Milburn. (2004). G‐CSF enables completion of tuberculosis therapy associated with iatrogenic neutropenia: Fig. 1.—. European Respiratory Journal. 23(4). 649–650. 10 indexed citations
11.
Jones, Richard W., Robert Knight, Sal Rassam, et al.. (2003). An update of the use and outcomes of the new immunomodulatory agent CC-4047 (Actimid) in patients with relapsed/refractory myeloma.. Blood. 102(11). 7 indexed citations
12.
Morris, Emma, Charles Craddock, D Milligan, et al.. (2002). Long-term follow-up of an alemtuzumab (CAMPATH-1H) containing reduced intensity allogeneic transplant regimen for non-Hodgkin's lymphoma (NHL).. UCL Discovery (University College London). 2 indexed citations
13.
Phekoo, Karen, Henrik Møller, David Bevan, Sue Bell, & Steve Schey. (2002). Engaging clinicians with a cancer registry improves ascertainment rates in haematological malignancies.. Blood. 100(11). 1 indexed citations
14.
Phekoo, Karen, Henrik Møller, Mike Richards, & Steve Schey. (2002). Comparison of a specialist haematological malignancy database against a regional cancer registry: case ascertainment and diagnostic accuracy. British Journal of Haematology. 119(3). 697–705. 9 indexed citations
15.
16.
Masters, Samuel H., et al.. (2000). New treatments for advanced cancer: an approach to prioritization. British Journal of Cancer. 83(10). 1268–1273. 17 indexed citations
17.
Lunn, Michael P., et al.. (1999). Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. Journal of Neurology Neurosurgery & Psychiatry. 66(5). 575–580. 72 indexed citations
18.
Prentice, H. G., Ian Hann, Raoul Herbrecht, et al.. (1997). A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. British Journal of Haematology. 98(3). 711–718. 324 indexed citations
19.
Williams, Alan, et al.. (1993). A Randomised Trial of Cyclophosphamide With and Without Low Dose Alpha-Interferon in the Treatment of Newly Diagnosed Myeloma. Leukemia & lymphoma. 9(3). 243–246. 5 indexed citations
20.
Giles, Frank, John Richards, Jeffrey Tobias, et al.. (1992). Prospective randomised study of double hemi-body irradiation with and without subsequent maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myeloma. European Journal of Cancer. 28(8-9). 1392–1395. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H Demuynck Breakdown of academic impact, for papers by Naohito Fujishima Breakdown of academic impact, for papers by A. C. Newland Breakdown of academic impact, for papers by Akiyoshi Miwa Breakdown of academic impact, for papers by Jean El Cheikh Breakdown of academic impact, for papers by Roberta Schiavo Breakdown of academic impact, for papers by P Ernst Breakdown of academic impact, for papers by Jae‐Ho Yoon Breakdown of academic impact, for papers by Valérie Coiteux Breakdown of academic impact, for papers by Anna Gayà
Rankless by CCL
2026